Anthrax Bioterrorism: Prevention, Diagnosis and Management Strategies | OMICS International | Abstract
ISSN: 2157-2526

Journal of Bioterrorism & Biodefense
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Anthrax Bioterrorism: Prevention, Diagnosis and Management Strategies

Robert A Fowler1* and Shirin Shafazand2

1Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

2University of Miami, Miller School of Medicine, Miami, USA

*Corresponding Author:
Robert A Fowler
Sunnybrook Health Sciences Centre
University of Toronto
2075 Bayview Avenue, Room D478
Toronto, Ontario, Canada, M4N 3M5
Tel: 416-480-6100-7471
Fax: 416-480-6191
E-mail: [email protected]

Received Date: December 11, 2010; Accepted Date: April 21, 2011; Published Date: April 23, 2011

Citation: Fowler RA, Shafazand S (2011) Anthrax Bioterrorism: Prevention, Diagnosis and Management Strategies. J Bioterr Biodef 2:107. doi: 10.4172/2157-2526.1000107

Copyright: © 2011 Fowler RA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Bacillus anthracis is one of a limited number of biological agents capable of causing death and disease in sufficient numbers to devastate an urban setting. In October 2001, reports of American patients with inhalational anthrax reacquainted the public with this ancient disease and introduced the harsh reality of a bioterrorist act. Cutaneous disease, gastrointestinal anthrax and inhalational disease are the known clinical manifestations of anthrax. Inhalational anthrax has an untreated mortality of nearly 100% and is the primary cause of death for an exposed and unprotected population. Vaccination affords a high degree of primary prevention and multiple effective antibiotics exist for both disease prevention and treatment. In this article, we will discuss the costs and effectiveness of prevention strategies, diagnosis, and therapy of bioterrorism related anthrax.